Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Myron Liebhaber

Allergy & Immunology Santa Barbara, CA Medical Doctor

NPI 1346253390 CMS profile 197471

215 Pesetas Ln, Santa Barbara, CA 93110

Open in the dashboard

General payments

$354,094

988 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,710 paid to institutions, not to them · program years 2021–2022

Through program year 2025, Myron Liebhaber of Santa Barbara, CA is reported in the CMS Open Payments database as having received $354,094 across 988 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,710 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,389 90
2024 General $22,743 76
2023 General $42,563 96
2022 General $44,234 136
2021 General $32,243 108
2020 General $44,479 142
2019 General $146,442 340

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Myron Liebhaber
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Myron Liebhaber were reported at $21,389. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Myron Liebhaber Allergy & Immunology median Middle half National median
2019 $146,442 $594 $163–$1,512 $163
2020 $44,479 $426 $106–$1,233 $114
2021 $32,243 $638 $157–$1,708 $132
2022 $44,234 $790 $205–$1,961 $149
2023 $42,563 $852 $220–$2,147 $160
2024 $22,743 $865 $203–$2,267 $164
2025 $21,389 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Shire North American Group Inc $110,678 152 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $67,347 131 payments
  3. Pharming Healthcare, Inc. $57,482 96 payments
  4. Phadia US Inc. $38,740 45 payments
  5. Grifols USA, LLC $21,787 59 payments
  6. CSL Behring $18,233 66 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $16,239 48 payments
  8. Pfizer Inc. $6,763 47 payments
  9. BioCryst Pharmaceuticals, Inc. $4,935 9 payments
  10. Genentech USA, Inc. $2,078 12 payments
  11. Other $9,812 323 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $178,996 76 payments
  2. Honoraria $59,815 33 payments
  3. Consulting Fee $56,133 21 payments
  4. Travel and Lodging $39,561 158 payments
  5. Food and Beverage $19,337 690 payments
  6. Education $251 10 payments
Products named General payments · program years 2019–2025
  1. CINRYZE $164,972 196 payments
  2. RUCONEST $57,482 96 payments
  3. ImmunoCAP $38,740 45 payments
  4. Xembify $21,397 44 payments
  5. Andembry $10,549 14 payments
  6. EUCRISA $6,616 37 payments
  7. HYQVIA $3,377 12 payments
  8. TAKHZYRO $3,153 41 payments
  9. Xolair $2,078 12 payments
  10. Orladeyo $1,812 23 payments
  11. Other $12,278 510 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,223

Median for Allergy/ Immunology: 449

Drug cost

$1,867,201

Median for Allergy/ Immunology: $169,700

Branded share of claims

62.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Takhzyro Lanadelumab-Flyo Brand 23 $1,156,260
Xembify Immune Globulin,gamma(Igg)klhw Brand 26 $196,734
Cutaquig Immun Glob G(Igg)-Hipp/Maltose Brand 15 $104,076
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $101,042
Icatibant Icatibant Acetate Brand 22 $78,081
Dupixent Pen Dupilumab Brand 11 $40,911
Xolair Omalizumab Brand 12 $34,801
Breo Ellipta Fluticasone/Vilanterol Brand 84 $33,813
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $28,533
Spiriva Respimat Tiotropium Bromide Brand 30 $21,789

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$44,627

Of which drugs: $6,840

Medicare patients

265

Average age 74

Services billed

1,381

181 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 57%
Depression 25%
Osteoporosis 23%
Chronic kidney disease 22%
Diabetes 21%
Ischemic heart disease 21%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 15 15 $1,227

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RUCONEST
$12,382 — —
Xembify
$3,545 26 —
DUPIXENT
$308 11 —
XOLAIR
$203 12 —
Orladeyo
$157 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

988 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record